Investment analysts at JMP Securities started coverage on shares of Gamida Cell (NASDAQ:GMDA) in a research note issued on Friday, September 20th, Marketbeat reports. The firm set an “outperform” rating and a $16.00 price target on the stock. JMP Securities’ price target suggests a potential upside of 261.17% from the stock’s previous close.
A number of other brokerages have also recently commented on GMDA. Oppenheimer set a $18.00 price target on Gamida Cell and gave the company a “buy” rating in a research note on Wednesday, August 7th. Zacks Investment Research upgraded Gamida Cell from a “hold” rating to a “buy” rating and set a $4.00 price target for the company in a research note on Monday, August 12th. Finally, ValuEngine upgraded Gamida Cell from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Gamida Cell currently has an average rating of “Buy” and a consensus price target of $16.43.
NASDAQ:GMDA traded up $0.17 during trading hours on Friday, reaching $4.43. 9,102 shares of the company were exchanged, compared to its average volume of 33,519. The business has a 50 day moving average of $4.11 and a 200 day moving average of $6.08. The company has a debt-to-equity ratio of 0.23, a current ratio of 4.47 and a quick ratio of 4.47. Gamida Cell has a 1-year low of $2.93 and a 1-year high of $15.41. The company has a market capitalization of $107.30 million and a P/E ratio of -0.42.
Gamida Cell (NASDAQ:GMDA) last released its earnings results on Tuesday, August 6th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.32). As a group, equities research analysts anticipate that Gamida Cell will post -1.16 earnings per share for the current fiscal year.
A number of large investors have recently made changes to their positions in the stock. Edmond DE Rothschild Holding S.A. acquired a new stake in Gamida Cell during the 1st quarter worth about $53,000. Royal Bank of Canada acquired a new stake in Gamida Cell during the 2nd quarter worth about $71,000. Bank Hapoalim BM acquired a new stake in Gamida Cell during the 2nd quarter worth about $195,000. EcoR1 Capital LLC acquired a new stake in Gamida Cell during the 2nd quarter worth about $265,000. Finally, Noked Capital LTD acquired a new stake in Gamida Cell during the 2nd quarter worth about $1,035,000. 25.86% of the stock is owned by institutional investors and hedge funds.
About Gamida Cell
Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
Recommended Story: NASDAQ Stock Market Explained
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.